BioRN Annual Conference 2019 - 11 November
Since 2009, each year the BioRN Annual Conference has been a valuable source of top information, lively discussions and networking opportunities with international experts from different fields of the life sciences.
Artificial Intelligence meets Health
- from desk to bench to bedside -
Date and location:
11 November, 09:30 am
German Cancer Research Center, Heidelberg
Deadlines:
Registration - 6 November
Abstracts and Posters - early submission July 31
- late submission September 15
The conference is booked out!
Current and future breakthroughs in artificial intelligence and machine learning have taken root in biotech and have huge potential to change how healthcare is delivered. Computing technologies promise to make drug discovery cheaper and quicker and machine learning techniques can immediately use the true result to improve diagnostic tests.
Algorithms can sift through countless publications almost instantaneously to find evidence in literature to interpret data and therapeutic options of a specific case. Machine and deep learning models can also analyse images in radiology and pathology, with an accuracy and speed that the human brain, no matter how well trained, simply cannot match.
The BioRN Annual Conference 2019 aims to provide an overview on current and future application of artificial intelligence and machine learning contributing to improve health, at different stages.

Welcome:
Theresia Bauer - Minister of Science, Research and the Arts, Member of the State Government of Baden-Württemberg
Key note speakers:
Stefan Hell - Max Planck Institute for Medical Research, Heidelberg and Max Planck Institute for Biophysical Chemistry, Göttingen
and Nobel Laureate in Chemistry in 2014
Lindsay Edwards - Head of AI/ML for UK & Europe - Glaxo Smith Kline
Confirmed Speakers:
• Sergey Biniaminov - HS Analysis
• Adrian Carter - Boehringer Ingelheim
• Lars Greiffenberg - AbbVie
• Maria de Kleijn - Elsevier
• Brandon Malone - NEC Laboratories Europe GmbH
• Patrick Most - University Hospital Heidelberg, Jefferson University and AaviGen GmbH
• Friedrich Rippmann - Merck
• Ute Schepers - Karlsruhe Institute of Technology (KIT) and VasQlab
• Oliver Stegle - German Cancer Research Center (DKFZ) and European Molecular Biology Laboratory (EMBL)
• Rebecca Wade - Heidelberg Institute for Theoretical Studies (HITS) and Heidelberg University
The conference is for BioRN members, associated and friends.
Key Public Partner: